Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5439305 | 0.98 | KDM4E (0.33) | KDM4EPOLBMAPK1ATMCHKA | |
| SCHEMBL5449885 | 0.94 | KDM4E (0.32) | KDM4EPOLBMAPK1ATM | |
| Trifluoromethanesulfonic Acid SCHEMBL5445950 | 0.89 | KDM4E (0.36) | KDM4EPOLBMAPK1ATM | |
| Hydrochloric Acid SCHEMBL5444909 | 0.88 | KDM4E (0.32) | KDM4EPOLBMAPK1ATM | |
| Bromide SCHEMBL5445824 | 0.86 | KDM4E (0.32) | KDM4EPOLBMAPK1ATMCHKA | |
| SCHEMBL5442180 | 0.83 | KDM4E (0.31) | KDM4EPOLBMAPK1ATM | |
| Trifluoromethanesulfonic Acid SCHEMBL5446074 | 0.78 | KDM4E (0.35) | KDM4EPOLBMAPK1ATM | |
| Hydrochloric Acid SCHEMBL30969435 | 0.75 | XDH (0.35) | — | |
| SCHEMBL19465050 | 0.73 | KMT2A (0.42) | POLB | |
| Hydrochloric Acid SCHEMBL5450114 | 0.72 | KDM4E (0.30) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021615-A1 | Imidazolium salts that can be immobilized | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | claimed |
| US-20070021615-A1 | Imidazolium salts that can be immobilized | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
| US-20060293526-A1 | Immobilised imidazoles and ruthenium catalysts | MERK PATENT GMBH (DE) | 2006-12-28 | — | — | US | disclosed |
| US-20060287450-A1 | Immobilizable ruthenium catalysts having n-heterocyclic carbene ligands | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2006-12-21 | — | — | US | disclosed |
| US-20060270547-A1 | N-heterocyclic carbenes that can be immobilized | MERCK PATENT GMBH (DE) | 2006-11-30 | — | — | US | disclosed |
| EP-1658297-A1 | IMIDAZOLIUM SALTS THAT CAN BE IMMOBILIZED | MERCK PATENT GmbH (DE) | 2006-05-24 | — | — | EP | disclosed |
| EP-1654064-A2 | IMMOBILISED IMIDAZOLES AND RUTHENIUM CATALYSTS | MERCK PATENT GmbH (DE) | 2006-05-10 | — | — | EP | disclosed |
| EP-1654062-A1 | IMMOBILIZABLE RUTHENIUM CATALYSTS HAVING N-HETEROCYCLIC CARBENE LIGANDS | MERCK PATENT GmbH (DE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016522-A1 | IMMOBILIZABLE RUTHENIUM CATALYSTS HAVING N-HETEROCYCLIC CARBENE LIGANDS | MERCK PATENT GMBH (DE) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016524-A2 | IMMOBILISED IMIDAZOLES AND RUTHENIUM CATALYSTS | MERCK PATENT GMBH (DE) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016940-A1 | IMIDAZOLIUM SALTS THAT CAN BE IMMOBILIZED | MERCK PATENT GMBH (DE) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287450-A1 | Immobilizable ruthenium catalysts having n-heterocyclic carbene ligands | NUDC, NSFL1C, ORC3 | KDM4E 3648/4885POLB 4030/4885MAPK1 3816/4885 |
| US-20060270547-A1 | N-heterocyclic carbenes that can be immobilized | SIRT3, B3GNT2, SIRT2 | KDM4E 1439/4885POLB 3968/4885MAPK1 4334/4885 |
| US-20070021615-A1 | Imidazolium salts that can be immobilized | IDH1, IDH3B, MIF | KDM4E 1831/4885POLB 2157/4885MAPK1 3529/4885 |
| US-20060293526-A1 | Immobilised imidazoles and ruthenium catalysts | PIN4, MIF, SCO2 | KDM4E 2727/4885POLB 2662/4885MAPK1 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.